Status:
COMPLETED
Comparison of Safety and Efficacy of de Novo Everolimus
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Cytomegalovirus Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Nowadays, de novo everolimus regimen in renal transplant patients is considered for reduction of cyclosporine dose and it is mentioned that this regimen not only has similar safety and efficacy, but a...
Detailed Description
This randomized clinical trial was conducted in Shahid Labbafi nejad hospital. 35 renal transplanted patients enter the study and randomized to one of two groups: everolimus or control (Sandimmun or t...
Eligibility Criteria
Inclusion
- Adult Transplanted patients \> 18 years
Exclusion
- Simultanous Kidney -Pancreas Transplantation
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2020
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04906304
Start Date
January 1 2020
End Date
August 1 2020
Last Update
May 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nooshin Dalili
Tehran, Iran